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ABSTRACT
Objectives: To determine whether current influenza vaccination is associated with reduced risk of
major vascular events in patients with recent ischemic stroke or TIA of mainly atherothrombotic
origin.
Methods: Data were pooled from 2 prospective cohort studies, the OPTIC Registry (n 5 3,635)
and the AMISTAD Study (n5 618), and from the randomized PERFORM Trial (n5 19,120), all of
which included patients with recent ischemic stroke or TIA. Influenza vaccination status was
determined in 23,110 patients. The primary outcome was a composite of nonfatal myocardial
infarction, nonfatal stroke, or vascular death up to 2 years. Secondary outcomes were myocardial
infarction and stroke separately.
Results: Influenza vaccination had no association with the primary outcome in the propensity
score–matched cohort (hazard ratio 0.97, 95% confidence interval [CI] 0.85–1.11; p 5 0.67)
or in the propensity score–adjusted cohort (hazard ratio 1.00, 95% CI 0.89–1.12; p 5 0.99).
Similarly, the risk of stroke and myocardial infarction did not differ between the vaccinated group
and the unvaccinated group; in the matched cohort, the hazard ratio was 1.01 (95% CI 0.88–
1.17; p 5 0.89) for stroke and 0.84 (95% CI 0.59–1.18; p 5 0.30) for myocardial infarction.
Conclusions: Influenza vaccination was not associated with reduced outcome events in patients
with recent atherothrombotic ischemic stroke after considering all baseline characteristics (including
concomitant medications) associated with influenza vaccination. Neurology® 2014;82:1905–1913
GLOSSARY
AMISTAD 5 Asymptomatic Myocardial Ischemia in STroke and Atherosclerotic Disease; CI 5 confidence interval; OPTIC 5
Outcomes in Patients with TIA and Cerebrovascular disease; PERFORM5 Prevention of cerebrovascular and cardiovascular
Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack.
There is increasing evidence that influenza infection could be a trigger for stroke and other major
vascular events. Various observational studies have reported a close temporal association between
influenza and the occurrence of stroke, suggesting a potential causal link.1–5 However, whether
immunizing patients against influenza reduces the risk of major vascular events remains uncer-
tain. Two case-control studies, one involving 90 patients and the other 370 patients with a
recent stroke, showed that influenza vaccination in the previous year was associated with a 50%
reduction in the odds of stroke,6,7 whereas another case-control study found no association.8
Two large cohort studies in populations older than 65 years suggested a reduced rate of stroke in
those vaccinated against influenza.9,10 To date, no randomized trial has tested the effect of
influenza vaccination on major vascular event recurrence in stroke patients, and conflicting
results have been found in patients with coronary artery disease.11–14 A healthy user bias may
explain the beneficial effect observed in these observational studies because it was recently shown
in a large observational study using data from a large multinational study that influenza vacci-
nation was associated with a far greater benefit effect on vascular events than expected,
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suggesting bias.15 Propensity score matching
may help to estimate the effect of an interven-
tion such as influenza vaccination by account-
ing for covariates that predict receiving the
treatment, matching attempts to mimic ran-
domization by creating a treated sample com-
parable to the untreated sample.16
In the present study, we aimed to evaluate
whether influenza vaccination was associated
with lower risk of major cardiovascular events
in patients with recent ischemic stroke or TIA
enrolled in 2 cohort studies and one randomized
trial, using propensity score–adjustment ap-
proaches to minimize confounding bias.
METHODS Data sources. Data from 3 prospective studies of
patients with a recent ischemic stroke or TIA were combined to
determine the impact of vaccination against influenza on recur-
rent cardiovascular events: the single-center Asymptomatic
Myocardial Ischemia in STroke and Atherosclerotic Disease
(AMISTAD) Study, designed to assess the prevalence and
impact of systemic atherosclerosis on the risk of major vascular
events17; the international multicenter Outcomes in Patients
with TIA and Cerebrovascular disease (OPTIC) Registry,
designed to evaluate determinants of 2-year recurrence risk in
patients with noncardioembolic ischemic stroke18; and the
international, multicenter, randomized Prevention of
cerebrovascular and cardiovascular Events of ischemic origin
with teRutroban in patients with a history oF ischemic strOke
or tRansient ischeMic attack (PERFORM) Trial, designed to
assess the superiority of terutroban, a specific TP receptor
antagonist, compared with aspirin in the prevention of
cardiovascular ischemic events in patients with recent
noncardioembolic ischemic stroke or TIA.19
Study patients. Eligible patients in the AMISTAD Study were
men or women aged 18 years or older who had a nondisabling
(Rankin Scale score,5) cerebral infarction documented by imag-
ing, or a TIA, in the previous 10 days.17 A total of 618 patients
were recruited between June 2005 and December 2008.
Follow-up visits were performed at 3 and 6 months, and at
1-year intervals thereafter; the minimum follow-up duration
was 4 years. The current analysis is based on the database lock
in December 2010, when the last patient completed 2-year
follow-up.
The OPTIC Registry enrolled patients aged 45 years or older
with a recent noncardioembolic TIA or minor stroke (,6 months),
in low- and middle-income countries. A total of 3,635 participants
were recruited from 245 sites in 17 countries between January 2007
and December 2008. Follow-up visits were performed every
6 6 1 months during the 2-year follow-up period.18
The PERFORMTrial enrolled patients with a recent noncar-
dioembolic cerebral ischemic event, such as ischemic stroke
within the previous 3 months, or TIA within the previous 8 days.
A total of 19,120 participants were recruited from 802 sites in 46
countries between February 2006 and April 2008. Follow-up vis-
its were performed at 1, 3, and 6 months, and every 6 months
thereafter; the minimum follow-up duration was 2 years.19
Standard protocol approvals, registrations, and patient
consents. All participants in the 3 studies provided written informed
consent before enrollment.
Data collection and definitions. Data on baseline character-
istics, medical history, and medications were collected from indi-
vidual patients at enrollment using a standardized form specific to
each study. Influenza vaccination status was determined by use of a
self-reported questionnaire at the enrollment visit in each study. In
the PERFORMTrial, influenza vaccination status was also recorded
at each follow-up visit. The primary study outcome was a composite
of nonfatal myocardial infarction, nonfatal stroke, or vascular death
up to 2 years. Secondary outcomes were myocardial infarction and
stroke separately (either fatal or nonfatal events). Events were
adjudicated in the AMISTAD Study and the PERFORM Trial
by blinded evaluation using medical records but were not
adjudicated in the OPTIC Registry.
Statistical analysis. Continuous variables are reported as
means 6 SDs. Categorical variables are reported as frequencies
and percentages. Patients were divided into 2 groups on the basis of
influenza vaccination at enrollment. Baseline characteristics, risk fac-
tors, and medications were compared between the 2 groups (for both
combined data and for data from the individual studies) using the
Student t test for continuous variables and the x2 test for categorical
variables. In view of the significant differences in key baseline char-
acteristics (table 1), we used propensity score matching to assemble a
cohort in which all of the measured baseline characteristics would be
well-balanced across groups.20 In each study separately, we estimated
a propensity score using a nonparsimonious multivariable logistic
regression model, with influenza vaccination use as the dependent
variable and all of the characteristics listed in table 1 as covariates.21
We therefore matched the selected vaccinated patients with
unvaccinated patients who had a similar propensity score by using
the greedymatching protocol (i.e., a 1:1 matching algorithmwithout
replacement) with a caliper width of 0.1.20,22 Once the matched pairs
were established, we pooled the 3 matched cohorts for the main
analysis. We estimated absolute standardized differences for all
covariates before and after matching to evaluate the bias reduction
using the propensity score matching method. An absolute
standardized difference of less than 10% for a given covariate
indicates an inconsequential imbalance.23 Comparisons in baseline
characteristics between the matched groups were done using the
paired Student t test and the Cochran-Mantel-Haenszel x2 test for
qualitative variables.
In the primary analysis, we performed survival analyses on the
matched cohort. Cumulative event curves were constructed using
the Kaplan-Meier method, and the event rates were determined
from 2-year Kaplan-Meier estimates. Events that occurred after
the 2-year follow-up were not included in the analysis. We com-
pared the risk of cardiovascular outcomes between the vaccinated
and unvaccinated groups using a Cox proportional hazard regres-
sion model stratified on the matched pairs. A first sensitivity anal-
ysis was done in the overall cohort using a Cox proportional
hazard regression model with the propensity score and study as
covariates.21 The proportional hazards assumption was verified
by using Schoenfeld residuals.
Because influenza vaccination status was recorded at each
follow-up visit in the PERFORM Trial, we also assessed the
impact of influenza vaccination in a time-varying Cox regression
analysis. This secondary sensitivity analysis, restricted to the
PERFORM Trial, attempted to account for changes in influenza
vaccination status over time by including a time-dependent cova-
riate into the propensity score–adjusted Cox model. In addition,
in the matched pooled cohort, we replicated the survival analyses
in each study separately, and performed key subgroup analyses
based on age (#75 vs.75 years), sex, qualifying event for inclu-
sion (stroke vs TIA), and history of coronary artery disease.
Heterogeneity across studies and subgroups was quantified by
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formal interaction tests. Given the statistically nonsignificant
results, we performed a post hoc power analysis using the observed
2-year event rate (10%). With 80% power, we could detect a
hazard ratio of 0.84 with 5,054 matched pairs and a hazard ratio
of 0.87 with the overall cohort (n5 23,110). Statistical testing was
conducted at the 2-tailed a level of 0.05, except for tests for homo-
geneity, in which an a level of 0.10 was chosen. Data were analyzed
using the SAS software version 9.3 (SAS Institute, Cary, NC).
RESULTS Among 23,353 patients enrolled in the
PERFORM Trial, the OPTIC Registry, and the
AMISTAD Study, 23,110 with available information
on influenza vaccination at baseline and with at least
one postbaseline follow-up assessment were included
in the present analysis (figure e-1 on the Neurology®
Web site at Neurology.org). Overall, 5,747 patients
Table 1 Patient characteristics according to vaccination status, before and after propensity score matching
Factor
Before propensity score matching After propensity score matching
NV (n 5 17,363) V (n 5 5,747) p NV (n 5 5,054) V (n 5 5,054) p
Age, y, mean (SD) 65.5 (8.4) 70.9 (7.8) ,0.001 69.9 (7.9) 70.0 (7.5) 0.55
Men 10,902 (62.8) 3,399 (59.1) ,0.001 3,034 (60.0) 3,049 (60.3) 0.76
Body mass index, kg/m2, mean (SD) 27.1 (4.4) 27.0 (4.3) 0.043 27.1 (4.4) 27.0 (4.2) 0.41
Systolic blood pressure, mm Hg, mean (SD) 138 (18) 138 (17) 0.62 138 (17) 138 (17) 0.82
Diastolic blood pressure, mm Hg, mean (SD) 81 (10) 78 (9) ,0.001 79 (10) 79 (9) 0.91
Qualifying event
Stroke 15,082 (86.9) 5,019 (87.3) 0.36 4,445 (88.0) 4,436 (87.8) 0.78
TIA 2,281 (13.1) 728 (12.7) 609 (12.0) 618 (12.2)
Region
Western Europe 4,946 (28.5) 3,210 (55.9) ,0.001 2,785 (55.1) 2,803 (55.5) 0.92
Eastern Europe 5,583 (32.2) 488 (8.5) 510 (10.1) 487 (9.6)
North America 214 (1.2) 268 (4.7) 185 (3.7) 187 (3.7)
South America 2,267 (13.1) 1,009 (17.6) 905 (17.9) 913 (18.1)
Asia 1,828 (10.5) 348 (6.1) 351 (6.9) 347 (6.9)
Oceania 266 (1.5) 309 (5.4) 206 (4.1) 209 (4.1)
Africa 1,272 (7.3) 89 (1.6) 88 (1.7) 86 (1.7)
Middle East 987 (5.7) 26 (0.5) 24 (0.5) 22 (0.4)
Medical history
Hypertension 14,479 (83.4) 4,773 (83.1) 0.55 4,192 (82.9) 4,179 (82.7) 0.73
Diabetes mellitus 4,971 (28.6) 1,692 (29.4) 0.24 1,512 (29.9) 1,492 (29.5) 0.66
Dyslipidemia 7,640 (44.1) 3,018 (52.6) ,0.001 2,610 (51.6) 2,600 (51.4) 0.84
Current smoking 4,960 (28.7) 1,019 (17.8) ,0.001 985 (19.5) 974 (19.3) 0.77
Known cardiovascular disease 3,666 (21.2) 1,250 (21.8) 0.37 1,017 (20.1) 1,075 (21.3) 0.15
Known coronary artery disease 3,551 (20.5) 1,086 (18.9) 0.009 873 (17.3) 911 (18.0) 0.31
Known peripheral artery disease 782 (4.5) 267 (4.7) 0.71 231 (4.6) 221 (4.4) 0.63
Medications
Aspirin 9,189 (52.9) 3,480 (60.6) ,0.001 3,050 (60.4) 3,025 (59.9) 0.60
Other antiplatelet agent 9,582 (55.2) 2,871 (50.0) ,0.001 2,426 (48.0) 2,482 (49.1) 0.26
Oral anticoagulant 1,304 (7.5) 614 (10.7) ,0.001 523 (10.4) 532 (10.5) 0.77
Angiotensin-converting enzyme inhibitor 8,802 (50.7) 2,668 (46.4) ,0.001 2,383 (47.2) 2,349 (46.5) 0.49
Calcium channel blocker 4,428 (25.5) 1,512 (26.3) 0.23 1,292 (25.6) 1,302 (25.8) 0.82
Diuretic 5,149 (29.7) 2,033 (35.4) ,0.001 1,711 (33.9) 1,734 (34.3) 0.62
b-Blocker 4,040 (23.3) 1,541 (26.8) ,0.001 1,284 (25.4) 1,299 (25.7) 0.73
Angiotensin II receptor blocker 2,220 (12.8) 1,076 (18.7) ,0.001 904 (17.9) 911 (18.0) 0.86
Statin 10,279 (59.2) 4,085 (71.1) ,0.001 3,570 (70.6) 3,517 (69.6) 0.24
Abbreviations: NV 5 patients not vaccinated against influenza; V 5 patients vaccinated against influenza.
Data are n (%) of patients unless otherwise indicated.
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(25%) were vaccinated against influenza at baseline:
5,174 from the PERFORM Trial (27%), 416 from
the OPTIC Registry (12%), and 157 from the
AMISTAD Study (27%).
As shown in table 1, there were significant differ-
ences in baseline characteristics between vaccinated
and unvaccinated patients. Compared with unvacci-
nated patients, vaccinated patients were on average
older, with a slightly higher percentage of women,
were more likely to be recruited in western Europe,
to be dyslipidemic, to have a lower diastolic blood
pressure, and to be taking aspirin, oral anticoagulants,
diuretics, b-blockers, angiotensin II receptors, and
statins. They were less likely to be current smokers,
to have a history of coronary artery disease, and to be
taking angiotensin-converting enzyme inhibitors.
The propensity score matched 5,054 vaccinated pa-
tients (88% of vaccinated patients) with 5,054 unvac-
cinated patients. There were no significant differences
in baseline characteristics between the 2 groups after
matching; all absolute standardized differences were
lower than 10%, suggesting an adequate match
(figure 1). The baseline characteristics for each study
before and after propensity score matching are shown
in tables e-1 to e-3; overall, there were no relevant
differences after propensity score matching in any of
the studies (figures e-2 to e-4).
In the overall matched cohort, 988 patients experi-
enced at least one primary event (vascular death, myo-
cardial infarction, or stroke) during the 2 years of
follow-up (Kaplan-Meier estimate, 10%). As shown
in figure 2, the rate for combined primary events in
vaccinated patients was similar to the rate in patients
who were not vaccinated (hazard ratio 0.97, 95% con-
fidence interval [CI] 0.85–1.11; p 5 0.67). Similar
results were found in the propensity score–adjusted
model including the entire study cohort (table 2).
There was no significant difference in the risk of sec-
ondary outcomes: the matched hazard ratio associated
with vaccination was 0.84 (95% CI 0.59–1.18; p 5
0.30) for myocardial infarction and 1.01 (95% CI
0.88–1.17; p 5 0.89) for stroke.
Although there was no significant heterogeneity
across studies (p 5 0.22), there was a nonsignificant
Figure 1 Absolute standardized differences in baseline characteristics between vaccinated and
unvaccinated patients before and after propensity score matching
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; CAD 5 coronary artery disease; CVD 5 cerebrovascular
disease; NV 5 not vaccinated against influenza; PAD 5 peripheral artery disease; V 5 vaccinated against influenza.
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decreased risk of combined primary events in vacci-
nated patients in comparison to unvaccinated patients
in the OPTIC Registry (figure e-5) (hazard ratio 0.71,
95% CI 0.47–1.05; p 5 0.09). A similar result was
observed for both myocardial infarction (hazard
ratio 0.53, 95% CI 0.23–1.26; p 5 0.15) and
stroke outcomes (hazard ratio 0.67, 95% CI
0.41–1.10; p 5 0.11) (table e-4). In the other
2 studies, no such differences were observed
(figures e-6 and e-7).
In vaccinated patients enrolled in the PERFORM
Trial, the proportion of patients who remained vacci-
nated during the study follow-up was 71% at 1 year
and 72% at 2 years. Of the unvaccinated patients at
enrollment, 12% were vaccinated at 1 year and
17% at 2 years. In time-varying analysis adjusted
for propensity score, influenza vaccination was not
associated with the combined outcome (hazard ratio
1.05, 95% CI 0.93–1.18; p5 0.42) or with myocar-
dial infarction alone (hazard ratio 1.02, 95% CI
0.75–1.37) or stroke alone (hazard ratio 1.08, 95%
CI 0.95–1.22).
The risks of the primary and secondary outcomes
in the propensity score–matched sample were similar
across subgroups of vaccinated and unvaccinated
patients (figure 3).
Figure 2 Cumulative incidence curve of cardiac death, myocardial infarction, and stroke by influenza
vaccination use in propensity score–matched sample
CI 5 confidence interval; CV 5 cardiovascular; HR 5 hazard ratio; MI 5 myocardial infarction.
Table 2 Risk of cardiovascular events in patients with and without influenza vaccination
Outcome
Propensity score–matched analysis Propensity score–adjusted analysisa
No. of events (Kaplan-Meier
estimates)
Hazard ratio
(95% CI)b p
No. of events (Kaplan-Meier
estimates)
Hazard ratio
(95% CI)c pNV (n 5 5,054) V (n 5 5,054) NV (n 5 16,901) V (n 5 5,672)
Nonfatal MI, nonfatal stroke,
vascular death
491 (10.0) 497 (10.1) 0.97 (0.85–1.11) 0.67 1,620 (9.9) 568 (10.3) 1.00 (0.89–1.12) 0.99
MI, fatal/nonfatal 78 (1.6) 64 (1.3) 0.84 (0.59–1.18) 0.30 253 (1.6) 83 (1.5) 0.82 (0.62–1.08) 0.15
Stroke, fatal/nonfatal 400 (8.2) 417 (8.5) 1.01 (0.88–1.17) 0.89 1,314 (8.1) 470 (8.5) 1.03 (0.91–1.16) 0.66
Abbreviations: CI 5 confidence interval; MI 5 myocardial infarction; NV 5 patients not vaccinated against influenza; V 5 patients vaccinated against
influenza.
a After excluding 537 patients with missing propensity score (2.7% of unvaccinated patients and 1.3% of vaccinated patients).
bCox-regression model stratified on the matched pairs.
c Cox-regression model stratified on study and adjusted on propensity score (introduced as continuous variable).
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DISCUSSION In this large, prospective, interna-
tional study, we found that after considering all base-
line characteristics associated with influenza
vaccination, current immunization against influenza
was not associated with a reduced risk of major
adverse vascular events in patients with a recent ische-
mic stroke or TIA. This result contradicts previous
positive cross-sectional studies.
Indeed, most epidemiologic studies published so
far reported an association between influenza vaccina-
tion and stroke risk.6,7,9,10 However, ours is not the
first negative study. A recent case-control study found
no association between stroke and influenza vaccina-
tion,8 and negative results have also been found in the
prevention of myocardial infarction.24–26 There is also
the possibility that, because of publication bias, other
negative studies have not been published. However,
above all, observational studies may be biased and this
is particularly true for influenza vaccination studies. It
has been suggested that a healthy user bias (also called
healthy vaccine bias) attributed to differences
between vaccinated and unvaccinated people may
account for some or all previously observed risk differ-
ences.27,28 Receipt of influenza vaccination is volun-
tary (even if recommended in fragile people) and thus
may be preferentially used by healthier individuals, as
illustrated by several inconsistencies. Observational
studies have reported that influenza vaccination is
Figure 3 Risk of cardiovascular events with use of influenza vaccination in propensity score–matched sample by key subgroup
*Qualifying event. Values are number of events/number of patients, unless otherwise indicated. Propensity score–matched HRs for use of influenza vac-
cination at baseline are reported with 95% CIs. CAD5 coronary artery disease; CI 5 confidence interval; CIV5 current influenza vaccination; HR5 hazard
ratio; MI 5 myocardial infarction.
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associated with a decrease in mortality of 50% or
more during the influenza season, whereas influenza
accounted for a maximum of 10% of all deaths, a risk
reduction that far exceeds the expected plausible pro-
tective effect.27 Moreover, a similar effect size has
been observed, while influenza vaccination did not
match the virus strain,29 and was even greater outside
the influenza season,30 suggesting the presence of con-
founding because vaccine effectiveness is expected to
occur only during the epidemic season. Finally, ben-
eficial effects, similar in magnitude to those observed
in the present study, were observed for diseases not
reasonably attributable to influenza infection, such as
hospitalization for trauma and injury.30 To limit this
bias inherent to the observational design of our study,
we used propensity score matching, a sophisticated
confounder modeling technique, and found no asso-
ciation between influenza vaccination and risk of a
major vascular event. This result offers further evi-
dence against the existence of a true positive effect
of vaccination in the prevention of vascular risk.
This study was based on a large sample size, and we
prospectively collected a considerable volume of data,
allowing us to use the propensity score matching tech-
nique. Results were confirmed in a sensitivity analysis
in the whole cohort, adjusted on the propensity score
and in key subgroups of patients. Our population is
quite homogeneous because only patients with a recent
ischemic stroke or TIA were included and most of
these events were related to atherosclerosis. Patients
were prospectively followed up during 2 years.
Our study does, however, also have limitations.
The present findings are derived from observational
analyses, which are subject to well-known limitations.
The first is the potential for confounding by mea-
sured or unmeasured variables, which cannot be ruled
out, even after propensity score adjustment methods.
In the present study, we had no information on life-
style or socioeconomic status, data that could have
influenced the vaccination status.28 For example,
one recent study using a large clinical database
from 2 randomized trials (the ONTARGET and
TRANSCEND trials), which enrolled 31,546 patients
with a history of vascular disease (approximately 20%
had a previous stroke or TIA) or diabetes mellitus with
end-organ damage, assessed the association between
influenza vaccination and the risk of a major vascular
event using a propensity score, but with different
covariates, including markers of healthy living.15
This study found that influenza was associated with a
strong decrease in major vascular events (31%–48%).
However, the authors concluded that despite all efforts
to limit bias, undetected bias probably explained their
results, because a similar benefit association was found
outside the epidemic period and a greater effect was
observed for noncardiovascular death (ranging from
73% to 79%), which is not supposed to be influenced
by influenza vaccination.15 We were unable to confirm
vaccination history with medical records, and
some patients may have been misclassified,
although self-report of vaccination history has a
high sensitivity and specificity.31 More importantly,
we cannot exclude an immortality time bias, despite
propensity score–matched analysis.32
In addition, most patients enrolled had noncar-
dioembolic stroke, because cardioembolic stroke was
an exclusion criterion in both the PERFORM Trial
and the OPTIC Registry. We cannot exclude that influ-
enza vaccination may have a beneficial effect in this par-
ticular subtype of ischemic stroke. The majority of our
population was taking antithrombotic therapies, antihy-
pertensive therapies, and lipid-lowering drugs, and
because of regular follow-up visits in specialized centers,
it is probable that vascular risk factors were strictly con-
trolled, leaving little room for any additional benefit from
influenza vaccination. Finally, we did not have informa-
tion about the matching between circulating virus strains
and the antigen in the vaccine in the different countries
studied, and we did not evaluate the effect of vaccination
in relation to the corresponding period of expected influ-
enza activity and inactivity. These are important limita-
tions because the protective effect of vaccination is
believed to be related to influenza infection prevention.
Data on influenza vaccination and vascular risk
have accumulated, including in stroke. The discrep-
ancy between published results is probably inherent
to bias, common in observational studies, but partic-
ularly difficult to apprehend in the context of influ-
enza vaccination. A large randomized placebo-
controlled trial would be needed to definitively
address whether influenza vaccination reduces the risk
of major vascular events in stroke patients, although it
is unlikely that such a trial will be funded. However,
the conflicting results found in studies in patients
with coronary heart disease show that many factors
come into play and that the choice of study popula-
tion is particularly important. For example, the effect
of vaccination appears greater in patients with unsta-
ble rather than stable coronary artery disease.11–14
Regarding cerebral infarction, the problem of etio-
logic subtypes is added to the list of factors to be
considered. In our study, with a majority of patients
with cerebral infarction of atherothrombotic origin,
vaccination was not associated with a reduced risk.
In a large cohort of patients with recent ischemic
stroke or TIAmatched for variables associated with influ-
enza vaccination, influenza vaccination was not associ-
ated with a reduction in the risk of major vascular events.
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